Get the latest cancer news and research. Sort by cancer type or read the current headlines to learn what’s happening in the science of cancer detection and treatment, as well as healthy living tips for dealing with cancer.
05
Medical doctors from the Burzynski Research Institute, Inc. (BRI) and the Burzynski Clinic (BC) in Houston, Texas will present case studies of patients with advanced liver and pancreatic cancers who were treated with combination gene- targeted therapies.
30
Pfizer Inc announced today the discontinuation of a Phase III study of its investigational agent axitinib for the treatment of advanced pancreatic cancer. Based on an interim analysis, an independent Data Safety Monitoring Board (DSMB) found no evidence of improvement in the primary endpoint of survival in patients treated with axitinib and gemcitabine, compared to gemcitabine alone, the current standard of care for patients with advanced pancreatic cancer.
19
GenVec, Inc. announced today top-line results of an interim analysis from its ongoing Phase III Pancreatic Cancer Clinical Trial with TNFerade (TM) (PACT) in patients with locally advanced pancreatic cancer. This interim analysis of overall survival, conducted after the 92nd death (one-third of total expected events), was designed to determine whether the study should continue and took place in the time frame originally estimated.
24
Infinity Pharmaceuticals, Inc. today announced that preclinical studies of IPI-926, Infinity's oral Hedgehog pathway inhibitor currently in Phase 1 clinical development, demonstrate that the compound significantly down-regulates Hedgehog signaling in tumor stroma, thereby disrupting the communication process between tumor and stroma, ultimately leading to tumor growth inhibition.
Accuray Incorporated, a global leader in the field of radiosurgery, announced today that treatments of extracranial tumors using the CyberKnife(R) Robotic Radiosurgery System increased by 38 percent worldwide during the fiscal year ending June 30, 2008. Specifically, during this time, prostate treatment grew approximately 95 percent worldwide, while lung, liver and pancreas treatments experienced double- digit growth.
23
A sponge that lives in the ocean depths off Florida's coastline holds a compound that might fight pancreatic and colon cancers. As one of their first projects in Florida, scientists at the Burnham Institute for Medical Research in Orlando have created a man-made version of the substance.
09
Pancreatic cancer is the fifth to sixth leading cause of cancer death in Europe and the fourth leading cause of cancer death in the USA. The lethality of this malignancy is demonstrated by the fact that the annual incidence is approximately equal to the annual deaths. Unfortunately, carcinoma of the pancreas is increasing in incidence, and its exact risk factors are poorly understood.
02
Pancreatic carcinoma is an obstinate disease that is difficult to deal with, the five-year survival rate is 4%. Conventional, the main treatments for pancreatic cancer are surgery, radiation therapy and chemotherapy. Despite advances in surgical and medical therapy, little effect has been made on the mortality rate of this disease.
U.S. researchers conducting a review study have determined CyberKnife is a safe treatment option for recurrent pancreatic cancer in some patients. Scientists at Georgetown University's Lombardi Comprehensive Cancer Center say pancreatic cancer is one of the most challenging malignancies to treat, and recurrence is common, even after initial treatment with surgery and radiation. When the cancer does return, treatment options are often limited to chemotherapy.
07
Doctors recommend diabetics undergo regular cancer screenings because not only are they at greater risk of developing kidney and circulatory disease, they also are at greater risk of developing tumours. Colon cancer is 30 percent more common in diabetics than in people without the disease and pancreatic cancer is 700 per cent more common, according to Germany's professional association for internists in Wiesbaden. Especially affected are patients with type 2 or adult onset diabetes.
We care about your feedback. Let us know how we can improve your CancerCompass experience.